{"prompt": "['Abbreviated Title: Ph II SGI110 in Peds & Adults', '39', 'Version Date: 07/22/2019', 'Adverse Events with Possible', 'Relations hip to SGI-110 (Guadecitabine)', 'Specific Protocol', '(CTCAE 5.0 Term)', 'Exceptions to Expedited', '[n= 757]', 'Reporting (SPEER)', 'Rare but Serious', 'Likely (>20%)', 'Less Likely (<=20%)', '(<3%)', 'Periorbital edema', 'GASTROINTESTINAL DISORDERS', 'Constipation', 'Constipation (Gr 2)', 'Diarrhea', 'Diarrhea (Gr2)', 'Mucositis oral', 'Mucositis oral (Gr 2)', 'Nausea', 'Nausea (Gr 2)', 'Vomiting', 'Vomiting (Gr 2)', 'GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS', 'Edema face', 'Fatigue', 'Fatigue (Gr 2)', 'Fever', 'Injection site reaction', 'Injection site reaction (Gr 2)', 'Pain', 'INFECTIONS AND INFESTATIONS', 'Infection\u00b2', 'INJURY, POISONING AND PROCEDURAL COMPLICATIONS', 'Bruising', 'Bruising (Gr 1)', 'INVESTIGATIONS', 'Lymphocyte count', 'Lymphocyte count decreased', 'decreased', '(Gr 4)', 'Neutrophil count', 'Neutrophil count decreased', 'decreased', '(Gr 2)', 'Platelet count decreased', 'Platelet count decreased (Gr', '2)', 'White blood cell', 'White blood cell decreased', 'decreased', '(Gr 2)', 'METABOLISM AND NUTRITION DISORDERS', 'Anorexia', 'Anorexia (Gr 2)', 'Tumor lysis syndrome', 'NERVOUS SYSTEM DISORDERS', 'Dizziness', 'Headache', 'PSYCHIATRIC DISORDERS', 'Insomnia', 'RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS']['Abbreviated Title: Ph II SGI110 in Peds & Adults', '40', 'Version Date: 07/22/2019', 'Adverse Events with Possible', 'Relations hip to SGI-110 (Guadecitabine)', 'Specific Protocol', '(CTCAE 5.0 Term)', 'Exceptions to Expedited', 'n= 757]', 'Reporting (SPEER)', 'Rare but Serious', 'Likely (>20%)', 'Less Likely (<=20%)', '(<3%)', 'Dyspnea', 'Epistaxis', 'SKIN AND SUBCUTANEOUS TISSUE DISORDERS', 'Purpura', 'Rash maculo-papular', 'This table will be updated as the toxicity profile of the agent is revised. Updates will be distributed', 'to all Principal Investigators at the time of revision. The current version can be obtained by', 'contacting PIO@CTEP.NCI.NIH.GOV. Your name, the name of the investigator, the protocol and', 'the agent should be included in the e-mail.', '2Infection may include any of the 75 infection sites under the INFECTIONS AND INFESTATIONS', 'SOC.', 'Adverse events reported on SGI-110 (Guadecitabine) trials, but for which there is insufficient', 'evidence to suggest that there was a reasonable possibility that SGI-110 (Guadecitabine)', 'caused the adverse event:', 'BLOOD AND LYMPHATIC SYSTEM DISORDERS - Blood and lymphatic system disorders -', 'Other (agranulocytosis); Blood and lymphatic system disorders - Other (coagulopathy); Blood and', 'lymphatic system disorders - Other (febrile bone marrow aplasia); Blood and lymphatic system', 'disorders - Other (histiocytos is hematophagic); Blood and lymphatic system disorders - Other', '(lymphadenopathy); Blood and lymphatic system disorders - Other (pancytopenia); Bone marrow', 'hypocellular; Leukocytosis; Thrombotic thrombocytopenic purpura', 'CARDIAC DISORDERS - Atrial fibrillation; Cardiac disorders - Other (atrial tachycardia);', 'Cardiac disorders - Other (bradycardia); Chest pain - cardiac; Heart failure; Left ventricular systolic', 'dysfunction; Palpitations; Sinus tachycardia', 'CONGENITAL, FAMILIAL AND GENETIC DISORDERS - Congenital, familial and genetic', 'disorders - Other (phimosis)', 'EAR AND LABYRINTH DISORDERS - Ear pain; Vertigo', 'ENDOCRINE DISORDERS - Adrenal insufficiency', 'EYE DISORDERS - Blurred vision; Eye disorders - Other (eye/retinal/conjunctival hemorrhage)', 'GASTROINTESTINAL DISORDERS - Abdominal distension; Abdominal pain; Belching;', 'Cheilitis; Colitis; Dry mouth; Dyspepsia; Dysphagia; Enterocolitis; Esophagitis; Flatulence;', 'Gastritis; Gastroesophageal reflux disease; Gastrointestinal disorders - Other (small intestinal', 'hemorrhage); Gastrointestinal disorders - Other (tongue discoloration); Gastrointestinal pain;']\n\n###\n\n", "completion": "END"}